LONDON, UK I April 03, 2020 I GSK is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products.
Supporting research and production of candidate COVID-19 vaccines
GSK’s initial response to the outbreak of COVID-19 has been to make our vaccine adjuvant technology available to scientists and organisations working on promising vaccine candidates and technology platforms. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.
Since announcing collaborations with the University of Queensland and Clover Biopharmaceuticals, we have expanded our collaborations and are now collaborating with several companies and research groups across the world, including in the USA and China.
Most recently, we have announced that GSK and Xiamen Innovax Biotech Co., Ltd. will collaborate to evaluate a recombinant protein-based coronavirus vaccine candidate (COVID-19 XWG-03), being developed by Innovax with Xiamen University. GSK will provide Innovax with its pandemic adjuvant system for preclinical evaluation of the COVID-19 vaccine. The COVID-19 XWG-03 vaccine candidate technology is based on a series of truncated S (spike) proteins which will be screened during the pre-clinical testing and a lead candidate will be determined by immunogenicity data.
Early indications of the adjuvant’s benefit have been reported in the first pre-clinical experiments by one of the collaborations. GSK expects data to be reported from the various collaborations over the next 3 months and these data will inform next steps for clinical development of the candidate vaccines.
GSK is evaluating further collaboration opportunities with several other companies and institutions. The company is also exploring options to share available manufacturing capacity, to help provide scale manufacturing and production for an eventual vaccine.
SOURCE: GlaxoSmithKline
Post Views: 600
LONDON, UK I April 03, 2020 I GSK is closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus. Since the outbreak, we have been actively exploring ways to help, with our science and expertise, alongside protecting the health and wellbeing of our people and managing our global supply chains to support patients and consumers who depend on our products.
Supporting research and production of candidate COVID-19 vaccines
GSK’s initial response to the outbreak of COVID-19 has been to make our vaccine adjuvant technology available to scientists and organisations working on promising vaccine candidates and technology platforms. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.
Since announcing collaborations with the University of Queensland and Clover Biopharmaceuticals, we have expanded our collaborations and are now collaborating with several companies and research groups across the world, including in the USA and China.
Most recently, we have announced that GSK and Xiamen Innovax Biotech Co., Ltd. will collaborate to evaluate a recombinant protein-based coronavirus vaccine candidate (COVID-19 XWG-03), being developed by Innovax with Xiamen University. GSK will provide Innovax with its pandemic adjuvant system for preclinical evaluation of the COVID-19 vaccine. The COVID-19 XWG-03 vaccine candidate technology is based on a series of truncated S (spike) proteins which will be screened during the pre-clinical testing and a lead candidate will be determined by immunogenicity data.
Early indications of the adjuvant’s benefit have been reported in the first pre-clinical experiments by one of the collaborations. GSK expects data to be reported from the various collaborations over the next 3 months and these data will inform next steps for clinical development of the candidate vaccines.
GSK is evaluating further collaboration opportunities with several other companies and institutions. The company is also exploring options to share available manufacturing capacity, to help provide scale manufacturing and production for an eventual vaccine.
SOURCE: GlaxoSmithKline
Post Views: 600
